EA8143

Kidney Cancer

A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy

Key Team Members

Principal Investigator

Steven A. Madden, MD

Research Coordinator

Taylor Knight

Not Accepting Patients

Check if You’re Eligible

(803) 935-8300

Research@lexhealth.org

About the Trial

The purpose of this study is to compare any good and bad effects of using nivolumab (also known as OPDIVO®), before and after the kidney cancer surgery to using the usual approach of surgically removing the kidney cancer followed by standard post-operative follow-up and monitoring.